Ask AI about Juvaris BioTherapeutics
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
AI-generated from reviews on this page. Verify anything important with the company directly.
0 Reviews
العربية
No reviews
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About Juvaris BioTherapeutics
Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.
The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.
- Website
- juvaris.com
- [email protected]
